Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%) attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.
Latagliata
Roberto
R
Dipartimento di Biotecnologie Umane ed Ematologia, Università "La Sapienza" di Roma, Via Benevento 6-00161, Rome, Italy. rob.lati@libero.it
Roberto
Latagliata
L
Breccia
Massimo
M
Massimo
Breccia
B
Carmosino
Ida
I
Ida
Carmosino
C
Sarlo
Chiara
C
Chiara
Sarlo
S
Montefusco
Enrico
E
Enrico
Montefusco
M
Mancini
Marco
M
Marco
Mancini
M
Natalino
Fiammetta
F
Fiammetta
Natalino
N
Chistolini
Antonio
A
Antonio
Chistolini
C
De Cuia
Rosa
R
Rosa
De Cuia
de C
Russo
Eleonora
E
Eleonora
Russo
R
Morano
Giacomo Salvatore
GS
Giacomo
Morano Salvatore
MS
Biondo
Francesca
F
Francesca
Biondo
B
Spadea
Antonio
A
Antonio
Spadea
S
Mandelli
Franco
F
Franco
Mandelli
M
Alimena
Giuliana
G
Giuliana
Alimena
A
D000367:Age Factors; D000368:Aged; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate